Breaking News Instant updates and real-time market news.

VIVE

Viveve

$2.47

0.12 (5.11%)

16:14
08/09/18
08/09
16:14
08/09/18
16:14

Viveve reports Q EPS (37c), consensus (38c)

Reports Q2 revenue $5.5M, consensus $5.19M. Cash and cash equivalents were $30.2 million as of June 30, 2018, a decrease of $8.2 million from $38.4 million as of March 31, 2018.

  • 09

    Aug

VIVE Viveve
$2.47

0.12 (5.11%)

06/19/18
MAXM
06/19/18
NO CHANGE
Target $9
MAXM
Buy
Maxim remains a buyer of Viveve shares after data report
Maxim analyst Anthony Vendetti would continue to be a buyer of Viveve shares after the company's report of positive interim 6-month data from its ongoing 12-month SUI feasibility study. He views SUI as another large market for the company and believes the company's multi-pronged approach of pursuing SUI and female sexual function indications can provide a significant competitive edge for the Viveve System. He maintains a Buy rating and $9 price target on Viveve shares.
07/11/18
MZHO
07/11/18
NO CHANGE
Target $4
MZHO
Buy
Viveve Q2 results 'step in the right direction,' says Mizuho
Mizuho analyst Difei Yang views Viveve Medical's preliminary Q2 results as a "step in the right direction" as revenue topped expectations and 2018 guidance was reaffirmed. However, it is "premature to declare victory," as the growth trend of treatment tips needs to be further understood, Yang tells investors in a research note. She keeps a Buy rating on Viveve with a $4 price target.
07/30/18
CHLM
07/30/18
NO CHANGE
CHLM
Hold
FDA warning to off-label competitors positive for Viveve, says Craig-Hallum
Craig-Hallum analyst Matt Hewitt noted that the FDA published seven "Letters to Industry" that were sent to companies that may be violating the law for inappropriately marketing their energy-based devices for vaginal "rejuvenation," but noted that Viveve (VIVE) was not amongst them. He views this as a positive for Viveve, as it signals that the FDA is cracking down on the off-label promotion that he thinks has been a key commercial challenge for the company. Viveve is the only one in the space currently performing a trial for sexual function, placing it "miles ahead of the competition" in terms of obtaining an actual label, added Hewitt, who keeps a Hold rating on the stock due to concerns over the company's operating cash flow burn and uncertainty about financials. The Fly notes that Cynosure, a unit of Hologic (HOLX), was among the companies to receive an FDA warning.
07/31/18
MZHO
07/31/18
NO CHANGE
Target $4
MZHO
Buy
Seven Viveve competitors get FDA warning letters, says Mizuho
The FDA issued a warning letter to seven competitors of Viveve Medical related to the inappropriate marketing of energy-based devices for the treatment of vaginal rejuvenation, Mizuho analyst Difei Yang tells investors in a research note. The analyst anticipates the competitors will likely stop marketing their devices "off label" in the near term. Since Viveve has not received a letter, Yang sees the development as a positive for the company. The letters to competitors will likely provide an opportunity to compete on equal footing with more established players, especially considering Viveve has received two investigational device exemptions from the FDA to conduct clinical trials in both sexual function and stress urinary incontinence, Yang tells investors in a research note. She reiterates a Buy rating on Viveve shares with a $4 price target.

TODAY'S FREE FLY STORIES

AYI

Acuity Brands

$161.46

3.9 (2.48%)

21:35
09/20/18
09/20
21:35
09/20/18
21:35
Upgrade
Acuity Brands rating change  »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

TTNP

Titan Pharmaceuticals

$0.50

-0.08 (-13.79%)

21:34
09/20/18
09/20
21:34
09/20/18
21:34
Syndicate
Titan Pharmaceuticals raises $9.5M in a public offering »

The securities offered by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MTEM

Molecular Templates

$5.81

-0.44 (-7.04%)

21:31
09/20/18
09/20
21:31
09/20/18
21:31
Syndicate
Molecular Templates 8.2M share Secondary priced at $5.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

YMAB

Y-mAbs Therapeutics

$0.00

(0.00%)

21:30
09/20/18
09/20
21:30
09/20/18
21:30
Syndicate
Y-mAbs Therapeutics 6M share IPO priced at $16.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

VKTX

Viking Therapeutics

$18.92

-0.72 (-3.67%)

21:28
09/20/18
09/20
21:28
09/20/18
21:28
Syndicate
Viking Therapeutics 9.5M share Secondary priced at $18.50 »

William Blair, SunTrust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

TWIN

Twin Disc

$23.33

0.34 (1.48%)

21:28
09/20/18
09/20
21:28
09/20/18
21:28
Syndicate
Twin Disc 1.333M share Secondary priced at $22.50 »

Baird and Oppenheimer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

FTCH

Farfetch

$0.00

(0.00%)

21:26
09/20/18
09/20
21:26
09/20/18
21:26
Syndicate
Farfetch 44.244M share IPO priced at $20.00, above the range »

Goldman Sachs, JPMorgan,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

CRSP

Crispr Therapeutics

$48.90

-3 (-5.78%)

21:25
09/20/18
09/20
21:25
09/20/18
21:25
Syndicate
Crispr Therapeutics 4.211M share Secondary priced at $47.50 »

Goldman Sachs, Piper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 21

    Sep

MDCA

MDC Partners

$4.55

0.25 (5.81%)

21:08
09/20/18
09/20
21:08
09/20/18
21:08
Hot Stocks
MDC Partners to evaluate strategic alternatives »

MDC Partners announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWRE

Guidewire

$101.71

0.16 (0.16%)

20:27
09/20/18
09/20
20:27
09/20/18
20:27
Hot Stocks
Guidewire sees 5-year target revenue of about $1.3B »

Sees % subscription of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

AVMXY

Avita Medical

$0.00

(0.00%)

20:13
09/20/18
09/20
20:13
09/20/18
20:13
Hot Stocks
Avita Medical announces FDA approval of RECELL in burn treatment »

AVITA Medica announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTS

Ladenburg Thalmann

$2.36

-0.03 (-1.26%)

20:05
09/20/18
09/20
20:05
09/20/18
20:05
Hot Stocks
Ladenburg Thalmann CEO to serve as chairman »

Ladenburg Thalmann…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

19:25
09/20/18
09/20
19:25
09/20/18
19:25
Conference/Events
Morgan Stanley multi-industrial analysts hold analyst/industry conference call »

U.S. Electrical Equipment…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

, SPX

S&P 500

$0.00

(0.00%)

19:15
09/20/18
09/20
19:15
09/20/18
19:15
General news
Trump's former lawyer Cohen met with Mueller multiple times, ABC says »

President Donald…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCS

Steelcase

$16.10

0.8 (5.23%)

, ACAD

Acadia

$19.08

3.97 (26.27%)

19:09
09/20/18
09/20
19:09
09/20/18
19:09
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SCS

Steelcase

$16.10

0.8 (5.23%)

ACAD

Acadia

$19.08

3.97 (26.27%)

TXN

Texas Instruments

$108.50

1.14 (1.06%)

MCD

McDonald's

$160.84

1.65 (1.04%)

RDS.A

Royal Dutch Shell

$66.83

0.57 (0.86%)

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

UNFI

United Natural Foods

$33.83

0.54 (1.62%)

MU

Micron

$46.06

1.01 (2.24%)

SGH

Smart Global

$30.44

0.7 (2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 01

    Oct

  • 04

    Oct

  • 10

    Oct

  • 28

    Oct

KORS

Michael Kors

$72.72

-0.33 (-0.45%)

19:01
09/20/18
09/20
19:01
09/20/18
19:01
Hot Stocks
Michael Kors names Andrea Pesaresi head of Men's business »

Michael Kors Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

19:00
09/20/18
09/20
19:00
09/20/18
19:00
Hot Stocks
Medtronic to acquire Mazor Robotics for $58.50 per ADS, or about $1.64B »

Medtronic (MDT) and Mazor…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

18:59
09/20/18
09/20
18:59
09/20/18
18:59
Hot Stocks
Breaking Hot Stocks news story on Medtronic, Mazor Robotics »

Medtronic to acquire…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:54
09/20/18
09/20
18:54
09/20/18
18:54
Upgrade
Acadia rating change at Piper Jaffray »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:48
09/20/18
09/20
18:48
09/20/18
18:48
Upgrade
Acadia rating change at Piper Jaffray »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SONA

Southern National Bancorp

$16.89

0.13 (0.78%)

18:45
09/20/18
09/20
18:45
09/20/18
18:45
Hot Stocks
Southern National Bancorp names Jeffrey Karafa CFO »

Southern National Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$298.32

-0.63 (-0.21%)

18:44
09/20/18
09/20
18:44
09/20/18
18:44
Periodicals
Tesla VP of global supply management O'Connor to leave company, Bloomberg says »

Liam O'Connor,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

  • 29

    Oct

CRBP

Corbus Pharmaceuticals

$7.90

2.75 (53.40%)

18:34
09/20/18
09/20
18:34
09/20/18
18:34
Hot Stocks
Corbus CEO says wants to be leading pipeline for synthetic endocannabinoids »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 01

    Oct

MCD

McDonald's

$160.84

1.65 (1.04%)

18:32
09/20/18
09/20
18:32
09/20/18
18:32
Hot Stocks
McDonald's says dividend hike reinforces confidence in long-term targets »

McDonald's says the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

MCD

McDonald's

$160.84

1.65 (1.04%)

18:31
09/20/18
09/20
18:31
09/20/18
18:31
Hot Stocks
McDonald's raises quarterly dividendy by 15% to $1.16 per share »

McDonald's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.